- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02077179
Health Improvement After Pregnancy (HIP) Program Randomized Control Trial (HIP)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Queen's Unviersity
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- must own or have daily access to one or more of the following; smart phone, tablet or laptop computer
Exclusion Criteria:
- Living greater than 100km from Kingston General Hospital
- Having an existing and long term contraindication to exercise at the time of recruitment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Standard of Care
Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
|
|
|
Expérimental: HIP Program
Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.
|
The entirety of the HIP Program is delivered through an interactive mobile website. The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment. The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Metabolic Syndrome Z Score
Délai: 32 weeks postpartum
|
The primary outcome measure is the metabolic syndrome (MetS) z score, a continuous score of the five metabolic syndrome variables that make up the Adult Treatment Panel (ATP) III diagnostic criteria (waist circumference, blood pressure, high density lipoprotein, triglycerides and glucose).
Differences between study arms will be compared.
|
32 weeks postpartum
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adherence to the HIP Program; Percent of Workouts Completed
Délai: 32 weeks postpartum
|
Adherence to the HIP Program will be assessed based on the number of times a participant indicates using the mobile website that a prescribed workout has been completed.
This outcome will only be measured in the intervention arm.
|
32 weeks postpartum
|
|
Differences in Biochemical Cardiovascular Risk Markers
Délai: 32 weeks postpartum
|
Differences between study arms for the following biochemical cardiovascular risk markers will be assessed at 32 weeks postpartum; lipid profile, fasting glucose, glycated hemoglobin, high sensitivity C-reactive protein, and urine microalbumin creatinine ratio.
|
32 weeks postpartum
|
|
Change in Anthropomorphic Measurements and Blood Pressure from Baseline at Midpoint
Délai: 20 weeks postpartum
|
Changes in systolic blood pressure, diastolic blood pressure and weight from baseline measures at 6-8 weeks postpartum will be assessed at the midpoint of the program at 20 weeks postpartum.
Differences between study arms will be compared.
|
20 weeks postpartum
|
|
Change in Anthropomorphic Measurements and Blood Pressure from Baseline at Study Completion
Délai: 32 weeks postpartum
|
Changes in systolic blood pressure, diastolic blood pressure and weight from baseline measures at 6-8 weeks postpartum will be assessed at the midpoint of the program at 32 weeks postpartum.
Differences between study arms will be compared.
|
32 weeks postpartum
|
|
Change in Anthropomorphic Measurements and Blood Pressure from Midpoint to Study Completion
Délai: 32 weeks postpartum
|
Changes in systolic blood pressure, diastolic blood pressure, weight, body mass index, hip circumference, and waist circumference from midpoint measures at 20 weeks postpartum will be assessed at the end of the program at 32 weeks postpartum.
Differences between study arms will be compared.
|
32 weeks postpartum
|
|
Adherence to the HIP Program; Percent of Step Counting Completed
Délai: 32 weeks postpartum
|
Adherence to the HIP Program will be assessed based on the number of times a participant uses the mobile website to log their daily step count total.
The number of times that the logged step count meets or exceeds the prescribed number of daily steps will also be assessed.
This outcome will only be measured in the intervention arm.
|
32 weeks postpartum
|
|
Adherence to the HIP Program; Percent of Dietary Logs Completed
Délai: 32 weeks postpartum
|
Adherence to the HIP Program will be assessed based on the number of times a participant uses the mobile website to enter the weekly dietary log.
The number of times that the dietary log meets the prescribed intake for each of the Canada's Food Guide food groups will also be assessed.
This outcome will only be measured in the intervention arm.
|
32 weeks postpartum
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Graeme N Smith, MD,PhD,FRCSC, Queen's University
Publications et liens utiles
Publications générales
- Smith GN, Pudwell J, Roddy M. The Maternal Health Clinic: a new window of opportunity for early heart disease risk screening and intervention for women with pregnancy complications. J Obstet Gynaecol Can. 2013 Sep;35(9):831-839. doi: 10.1016/S1701-2163(15)30841-0. No abstract available.
- Cusimano MC, Pudwell J, Roddy M, Cho CK, Smith GN. The maternal health clinic: an initiative for cardiovascular risk identification in women with pregnancy-related complications. Am J Obstet Gynecol. 2014 May;210(5):438.e1-9. doi: 10.1016/j.ajog.2013.12.001. Epub 2013 Dec 4.
- Smith GN, Pudwell J, Walker M, Wen SW. Risk estimation of metabolic syndrome at one and three years after a pregnancy complicated by preeclampsia. J Obstet Gynaecol Can. 2012 Sep;34(9):836-841. doi: 10.1016/S1701-2163(16)35382-8.
- Smith GN, Pudwell J, Walker M, Wen SW. Ten-year, thirty-year, and lifetime cardiovascular disease risk estimates following a pregnancy complicated by preeclampsia. J Obstet Gynaecol Can. 2012 Sep;34(9):830-835. doi: 10.1016/S1701-2163(16)35381-6.
- Smith GN, Walker MC, Liu A, Wen SW, Swansburg M, Ramshaw H, White RR, Roddy M, Hladunewich M; Pre-Eclampsia New Emerging Team (PE-NET). A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol. 2009 Jan;200(1):58.e1-8. doi: 10.1016/j.ajog.2008.06.035. Epub 2008 Aug 8.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- OBGY-249-14
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .